Recent developments in nanotechnology have provided new tools for both cancer imaging and treatment. The functionalization of the nanocarrier based drugs using biological ligands allows increasing specificity of drug targeting enhancing efficacy and reducing side effects. In this paper some current nanocarrier based drugs are described and the principles for their functionalization in cancer treatment and imaging are reviewed.
NijharaR., BalakrishnanK.Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine2006; 2: 127–36.
3.
PeerD., KarpJ.M., HongS., FarokhzadO.C., MargalitR., LangerR.Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol2007; 2: 751–60.
4.
TorchilinV.P.Multifunctional pharmaceutical nanocarriers: development of the concept, in multifunctional pharmaceutical nanocarriers. In TorchilinV, ed. Springer Science + Business Media2008; 1–32.
RowleyJ.D.A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Gimsa staining. Nature1973; 243: 290–3.
7.
WalshT., CasadeiS., CoatsK.H.. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA2006; 295: 1379–88.
SinghA.P., SenapatiS., PonnusamyM.P.. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol2008; 9: 1076–85.
10.
ByrneJ.D., BetancourtT., Brannon-PeppasL.Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev2008; 60: 1615–26.
11.
GolubT.R., SlonimD.K., TamayoP., HuardC., GaasenbeekM.. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science1999; 286: 531–7.
12.
PerouC.M., SorlieT., EisenM.B.. Molecular portraits of human breast tumours. Nature2000; 406: 747–52.
13.
EvansW.E., RellingM.V.Moving towards individualized medicine with pharmacogenomics. Nature2004; 429: 464–8.
14.
MoghimiS.M., HunterA.C., MurrayJ.C.Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev2001; 53: 283–318.
15.
MoghimiS.M., SzebeniJ.Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res2003; 42: 463–78.
16.
AdamsM.L., LavasanifarA., KwonG.S.Amphiphilic block copolymers for drug delivery. J Pharm Sci2003; 92: 1343–55.
17.
ChoK., WangX., NieS., ChenZ.G., ShinD.M.Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res2008; 14: 1310–6.
18.
WangZ., YangL., ChenZ., ShinD.Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin2008; 58: 97–110.
19.
CigadaA.Biomaterials, tissue engineering, gene therapy. Journal of Applied Biomaterials and Biomechanics2008; 6: 127–31.
20.
MaurerN., FenskeD.B., CullisP.R.Developments in liposomal drug delivery systems. Expert Opin Biol Ther2001; 1: 923–47.
LudwigH., Strasser-WeipplK., SchrederM., ZojerN.Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol2007; 18: 64–70.
23.
Perez-LopezM.E., CurielT., GomezJ.G., JorgeM.Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs2007; 18(suppl): ix611–7.
24.
SchwendenerR.A.Liposomes in biology and medicine. Adv Exp Med Biol2007; 620: 117–28.
SchiffelersR.M., StormG.Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int J Pharm2008; 364: 258–64.
27.
BanciuM., SchiffelersR.M., StormG.Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. Pharm Res2008; 25: 1948–55.
28.
KimT.Y., KimD.W., ChungJ.Y.. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res2004; 10: 3708–16.
29.
ZhangL., GuF.X., ChanJ.M., WangA.Z., LangerR.S., FarokhzadO.C.Nanoparticles in medicine: therapeutic applications and developments. Clin Pharm Ther2008; 83: 761–9.
30.
SvensonS.Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm2009; 71: 445–62.
31.
TekadeR.K., KumarP.V., JainN.K.Dendrimers in oncology: an expanding horizon. Chem Rev2009; 109: 49–87.
32.
MuthuM.S., SinghS.Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomed2009; 4: 105–18.
33.
IijimaS.Helical microtubules of graphitic carbon. Nature1991; 354: 56–8.
34.
LvovY.M., ShchukinD.G., MöhwaldH., PriceR.R.Halloysite clay nanotubes for controlled release of protective agents. ACS Nano2008; 2: 814–20.
35.
ChenJ., ChenS., ZhaoX., KuznetsovaL.V., WongS.S., OjimaI.Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc2008 Nov 14 [Epub ahead of print].
36.
WijayaA., SchafferS.B., PallaresI.G., Hamad-SchifferliK.Selective release of multiple DNA oligonucleotides from gold nanorods. ACS Nano2009; 3: 80–6.
37.
KimI., ParkY.H., ReyD.A., BattC.A.Silica-deposited phospholipid nanotubules as a plausible drug targeting system. J Drug Target2008; 16: 716–22.
38.
NanA., BaiX., SonS.J., LeeS.B., GhandehariH.Cellular uptake and cytotoxicity of silica nanotubes. Nano Lett2008; 8: 2150–4.
39.
BiancoA., KostarelosK., PratoM.Opportunities and challenges of carbon-based nanomaterials for cancer therapy. Expert Opin Drug Deliv2008; 5: 331–42.
40.
BiancoA., KostarelosK., PratoM.Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol2005; 9: 674–9.
41.
SchipperM.L., Nakayama-RatchfordN., DavisC.R.. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol2008; 3: 216–21.
42.
ManchesterM., SinghP.Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev2006; 58: 1505–22.
43.
HuangX., El-SayedI.H., QianW., El-SayedM.A.Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc2006; 128: 2115–20.
44.
ChenJ., WangD., XiJ.. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett2007; 7: 1318–22.
45.
GobinA.M., LeeM.H., HalasN.J., JamesW.D., DrezekR.A., WestJ.L.Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett2007; 7: 1929–34.
46.
GuoweiD., AdrianeK., ChenX., JieC., YinfengL.PVP magnetic nanospheres: biocompatibility, in vitro and in vivo bleomycin release. Int J Pharm2007; 328: 78–85.
47.
KohlerN., SunC., FichtenholtzA., GunnJ., FangC., ZhangM.Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small2006; 2: 785–92.
48.
MedarovaZ., PhamW., FarrarC., PetkovaV., MooreA.In vivo imaging of siRNA delivery and silencing in tumors. Nat Med2007; 13: 372–7.
49.
LiongM., LuJ., KovochichM.. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano2008; 2: 889–96.
50.
RieterW.J., PottK.M., TaylorK.M., LinW.Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc2008; 130: 11584–5.
51.
CarmelietP., JainR.K.Angiogenesis in cancer and other diseases. Nature2000; 407: 249–57.
52.
NorthfeltD.W., MartinF.J., WorkingP.. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol1996; 36: 55–63.
53.
NettiP.A., RobergeS., BoucherY.. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res1996; 52: 27–46.
54.
ChisholmE.J., VassauxG., DuqueP.M.. Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res2009; 69: 2655–2662.
KongG., AnyarambhatlaG., PetrosW.P.. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res2000; 60: 6950–7.
58.
WalshD., HallS.R., MoirA., WimbushS.C., PalazzoB.Carbonated water mediated preparation of poly(N-isopropylacrylamide) thermoresponsive gels and liquids. Biomacromolecules2007; 8: 3800–5.
59.
DeryuginaE.I., QuigleyJ.P.Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev2006; 25: 9–34.
60.
MansourA.M., DrevsJ., EsserN.. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin pro-drug that is cleaved by matrix metalloproteinase 2. Cancer Res2003; 63: 4062–66.
61.
AllenT.M.Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer2002; 2: 750–63.
62.
IafiscoM., PalazzoB., FaliniG.. Adsorption and conformational change of myoglobin on biomimetic hydro-xyapatite nanocrystals functionalized with alendronate. Langmuir2008; 24: 4924–30.
63.
TolcherA.W., SugarmanS., GelmonK.A.. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol1999; 17: 478–84.
64.
SanzL., BlancoB., Alvarez-VallinaL.Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks. Trends Immunol2004; 25: 85–91.
65.
van DijkM.A., van de WinkelJ.G., Human antibodies as next generation therapeutics. Curr Opin Chem Biol2001; 5: 368–74.
66.
ChapmanA.P.PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev2002; 54: 531–45.
67.
MaruyamaK., TakahashiN., TagawaT., NagaikeK., IwatsuruM.Immunoliposomes bearing polyethyleneglycol-coupled Fab’ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett1997; 413: 177–80.
68.
LeeL.S., ConoverC., ShiC., WhitlowM., FilpulaD.Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem1999; 10: 973–81.
69.
ChapmanA.P., AntoniwP., SpitaliM., WestS., StephensS., KingD.J.Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol1999; 17: 780–3.
70.
LeamonC.P., ReddyJ.A.Folate-targeted chemotherapy. Adv Drug Deliv Rev2004; 56: 1127–41.
71.
NieS., XingY., KimJ.G., SimonsJ.W.Nanotechnology applications in cancer. Annu Rev Biomed Eng2007; 9: 257–88.
72.
AlivisatosA.P.Semiconductor clusters, nanocrystals, and quantum dots. Science1996; 271: 933–7.
SmithA.M., DuanH., MohsM.A., NieS.Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev2008; 60: 1226–40.
75.
KimS.W., ZimmerJ.P., OhnishiS., TracyJ.B., FrangioniJ.V., BawendiM.G.Engineering InAsxP1-x/InP/ZnSe II-V alloyed core/shell quantum dots for the near-infrared. J Am Chem Soc2005; 127: 10526–32.
76.
EfrosA.L.Interband absorption of light in a semiconductor sphere. Sov Phys Semicond1982; 16: 772–5.
77.
EkimovA.I., OnushchenkoA.A.Quantum size effect in the optical-spectra of semiconductor micro-crystals. Sov Phys Semicond1982; 16: 775–8.
78.
BhattacharyaP., GhoshS., Stiff-RobertsA.D.Quantum dot opto-electronic devices. Annu Rev Mater Res2004; 34: 1–40.
79.
CrouchD., NoragerS., O'BrienP., ParkJ.H., PickettN.New synthetic routes for quantum dots. Philos Trans R Soc Lond2003; 361: 297–310.
80.
MurrayC.B., NorrisD.J., BawendiM.G.Synthesis and characterization of nearly monodisperse CdE (E=S, Se, Te) semiconductor nanocrystallites. J Am Chem Soc1993; 115: 8706–15.
81.
DabbousiD.O., Rodriguez-ViejoJ., MikulecF.V.. (CdSe) ZnS core-shell quantum dots: synthesis and characterization of a size series of highly luminescent nanocrystallites. J Phys Chem1997; 101: 9463–75.
82.
HinesM.A., ScholesC.D.Colloidal PbS nanocrystals with size-tunable near infrared emission: observation of post-synthesis se If-narrowing of the particle size distribution. Adv Mater2003; 15: 1844–9.
83.
GuoW., LiJ.J., WangY.A., PengX.G.Luminescent CdSe/CdS core/shell nanocrystals in dendron boxes: superior chemical, photochemical and thermal stability. J Am Chem Soc2003; 125: 3901–9.
RhynerM.N., SmithA.M., GaoX., MaoH., YangL., NieS.Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine2006; 1: 209–17.
86.
GaoX.H., CuiY.Y., LevensonR.M., ChungL.W.K., NieS.M.In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol2004; 22: 969–76.
87.
YuX.F., ChenL.D., LiK.Y.. Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. J Biomed Opt2007; 12: 014008.
88.
TadaH., HiguchiH., WanatabeT.M., OhuchiN.In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res2007; 67: 1138–44.
89.
CaiW.B., ShinD.W., ChenK.. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett2006; 6: 669–76.
90.
HoodJ.D., BednarskiM., FraustoR.. Tumor regression by targeted gene delivery to the neovasculature, Science2002; 296: 2404–7.
91.
NasongklaN., ShuaiX., AiH.. cRGD functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl2004; 43: 6323–7.
92.
BackerM.V., GaynutdinovT.I., PatelV.. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther2005; 4: 1423–9.
93.
LiL., WartchowC.A., DanthiS.N.. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys2004; 58: 1215–27.
94.
ChenJ., WuH., HanD., XieC.Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett2006; 231: 169–75.
95.
KondoM., AsaiT., KatanasakaY.. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer2004; 108: 301–6.
96.
HatakeyamaH., AkitaH., IshidaE.. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm2007; 342: 194–200.
97.
YamazakiN., KojimaS., BovinN.V.. Endogenous lectins as targets for drug delivery. Adv Drug Deliv Rev2000; 43: 225–44.
98.
SeymourL.W., FerryD.R., AndersonD.. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol2002; 20: 1668–76.
99.
RazA., MeromskyL., LotanR.Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells. Cancer Res1986; 46: 3667–72.
100.
LowP.S., AntonyA.C.Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev2004; 56: 1055–8.
101.
ParanjpeP.V., ChenY., KholodovychV.. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. J Control Release2004; 100: 275–92.
102.
YooH.S., ParkT.G.Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release2004; 100: 247–56.
103.
Kukowska-LatalloJ.F., CandidoK.A., CaoZ.. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res2005; 65: 5317–24.
104.
KamN.W., O'ConnellM., WisdomJ.A., DaiH.Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA2005; 102: 11600–5.
105.
Hu-LieskovanS., HeidelJ.D., BartlettD.W., DavisM.E., TricheT.J.Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res2005; 65: 8984–92.
106.
HeidelJ.D., YuZ., LiuJ.Y.. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA2007; 104: 5715–21.
107.
WuJ., LuY., LeeA.. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Sci2007; 10: 350–7.
108.
DavisM.E., ChenZ.G., ShinD.M.Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov2008; 7: 771–82.
109.
LiS.D., ChonoS., HuangL.Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther2008; 16: 942–6.
110.
BanerjeeR., TyagiP., LiS., HuangL.Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer2004; 112: 693–700.
111.
ChenH., GaoJ., LuY.. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release2008; 128: 209–16.
112.
SteinhauserI.M., LangerK., StrebhardtK.M., SpänkuchB.Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials2008; 29: 4022–8.
113.
TanW.B., JiangS., ZhangY.Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials2007; 28: 1565–71.
114.
TsengC., WangT., DongG.. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials2007; 28: 3996–4005.
115.
BhirdeA.A., PatelV., GavardJ.. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano2009; 3: 307–16.
116.
KellyK., JonesD.Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia2003; 5: 437–44.
117.
ChenH.W., MedleyC.D., SefahK.. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem2008; 3: 991–1001.
118.
FarokhzadO.C., ChengJ., TeplyB.A.. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA2006; 103: 6315–20.
